Literature DB >> 14560060

Agitation in Alzheimer's disease is a manifestation of frontal lobe dysfunction.

V Senanarong1, J L Cummings, L Fairbanks, M Mega, D M Masterman, S M O'Connor, T L Strickland.   

Abstract

OBJECTIVES: (1) To investigate the prevalence and characteristics of agitation in patients with Alzheimer's disease (AD) and other forms of dementia; (2) to explore the association between agitation and other clinical variables, including disease severity, functional impairment and other neuropsychiatric symptoms, and (3) to determine the predictors of agitation.
METHODS: Data for 427 men and women with dementia from outpatient clinics of the University of California, Los Angeles Alzheimer's Disease Center were analyzed. There were 277 patients with AD, 43 with vascular dementia, 47 with mixed dementia, 45 with frontotemporal dementia and 15 with dementia with Lewy bodies. Patients were evaluated with the Mini-Mental State Examination (MMSE), Neuropsychiatric Inventory (NPI), Functional Activities Questionnaire (FAQ), neuropsychological tests and the Caregiver Appraisal instrument. SPSS10 was utilized for statistical analysis.
RESULTS: There was no difference in agitation subscale scores among patients with dementia of various etiologies. In patients with AD, there was increased prevalence of agitation with increasing dementia severity. Agitation contributed substantially to caregiver burden and impact. There was a significant correlation between the FAQ and the NPI agitation subscale score after adjusting for MMSE scores. Delusion, disinhibition and irritability subscale scores in AD patients were correlated with agitation across disease severity. Subscale scores of frontally mediated behaviors including irritability, delusions and disinhibition predicted most of the variance in agitation levels.
CONCLUSION: Agitation is common in AD and other dementias and has a marked impact on caregivers. It is related to dementia severity and to specific types of associated psychopathology implicating frontal lobe dysfunction. The present study is the largest and most comprehensive assessment of agitation reported. The data suggest that agitation in AD is a frontal lobe syndrome. Frontal lobe dysfunction may predispose AD patients to agitation by exaggerating behavioral responses to many types of coexisting psychopathology or environmental provocations. Copyright 2004 S. Karger AG, Basel

Entities:  

Mesh:

Year:  2003        PMID: 14560060     DOI: 10.1159/000074080

Source DB:  PubMed          Journal:  Dement Geriatr Cogn Disord        ISSN: 1420-8008            Impact factor:   2.959


  22 in total

Review 1.  APP transgenic mice for modelling behavioural and psychological symptoms of dementia (BPSD).

Authors:  R Lalonde; K Fukuchi; C Strazielle
Journal:  Neurosci Biobehav Rev       Date:  2012-02-21       Impact factor: 8.989

2.  Drugs for Alzheimer's disease and related dementias.

Authors:  Serge Gauthier
Journal:  BMJ       Date:  2005-04-16

Review 3.  Alternatives to atypical antipsychotics for the management of dementia-related agitation.

Authors:  Michael J Passmore; David M Gardner; Yvette Polak; Kiran Rabheru
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

4.  Hallucinations and Delusions Signal Alzheimer's Associated Cognitive Dysfunction More Strongly Compared to Other Neuropsychiatric Symptoms.

Authors:  Joshua T Fuller; Tabina K Choudhury; Deborah A Lowe; Steve Balsis
Journal:  J Gerontol B Psychol Sci Soc Sci       Date:  2020-10-16       Impact factor: 4.077

5.  Behavioral and psychological symptoms of dementia and their management.

Authors:  Nilamadhab Kar
Journal:  Indian J Psychiatry       Date:  2009-01       Impact factor: 1.759

Review 6.  Memory loss in Alzheimer's disease: implications for development of therapeutics.

Authors:  Carl A Gold; Andrew E Budson
Journal:  Expert Rev Neurother       Date:  2008-12       Impact factor: 4.618

Review 7.  Neurologic and motor dysfunctions in APP transgenic mice.

Authors:  Robert Lalonde; Ken-Ichiro Fukuchi; Catherine Strazielle
Journal:  Rev Neurosci       Date:  2012       Impact factor: 4.353

8.  Clinically meaningful treatment responses after switching to galantamine and with addition of memantine in patients with Alzheimer's disease receiving donepezil.

Authors:  Osamu Kano; Hirono Ito; Takanori Takazawa; Yuji Kawase; Kiyoko Murata; Konosuke Iwamoto; Tetsuro Nagaoka; Takehisa Hirayama; Ken Miura; Riya Nagata; Tetsuhito Kiyozuka; Jo Aoyagi; Ryuta Sato; Teruo Eguchi; Ken Ikeda; Yasuo Iwasaki
Journal:  Neuropsychiatr Dis Treat       Date:  2013-02-15       Impact factor: 2.570

9.  Bipolar disorder: clinical perspectives and implications with cognitive dysfunction and dementia.

Authors:  R Lopes; L Fernandes
Journal:  Depress Res Treat       Date:  2012-05-28

10.  Behavioral and psychological symptoms of dementia: A study of symptomatology.

Authors:  S Shaji; Srija Bose; Shan Kuriakose
Journal:  Indian J Psychiatry       Date:  2009-01       Impact factor: 1.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.